The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Molecular and clinicopathologic evidence of heterogeneity in KRAS-mutant colon cancers.
Vlad Calin Popovici
No relevant relationships to disclose
Eva Budinska
No relevant relationships to disclose
Sabine Tejpar
Consultant or Advisory Role - Pfizer
Research Funding - Merck; Pfizer
Giovanni d'Ario
No relevant relationships to disclose
Antonio Fabio Di Narzo
No relevant relationships to disclose
John Graeme Hodgson
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Arnaud Roth
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Fred Bosman
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer
Mauro Delorenzi
No relevant relationships to disclose